| Methods |
See Mandel et al 1993 (Update of Minnesota study) |
| Participants |
See Mandel et al 1993 |
| Interventions |
See Mandel et al 1993
All Ss followed‐up until death or Aug 2002 (17 years after start of study); by 9th screening round, 19,654 Ss in Screen group still alive, 9,367 were invited as participated in previous 8 rounds and not diagnosed with colorectal neoplasia (including 41 Ss unfit for COL) |
| Outcomes |
Colorectal cancer mortality at 18 years follow‐up
Compliance with screening = Agrp 75%, Bgrp 78%
Agrp average of 3.7 screens in Phase I and 4.0 screens in Phase II; Bgrp average of 2.3 screens in Phase I and 2.1 screens in Phase II
95% Ss with positive screen received diagnostic follow‐up (5% declined to consult a physician); Agrp 83% and Bgrp 84% underwent complete COL or FSIG+DCBE
Number of CRC deaths: Agrp 121 (9.46/1000), Bgrp 148 (11.19/1000), Cgrp 121 (14.09/1000)
Deaths from all causes: Agrp 5236 (342/1000), Bgrp 5213 (340/1000), Cgrp 5186 (343/1000)
Cumulative CRC mortality ratio: Agrp 0.67 (CI: 0.51‐0.83); Bgrp 0.79 (CI: 0.62‐0.97), Cgrp 1.00
Duke's stage D: Agrp 47% fewer than control; Bgrp 32% fewer than control
Mortality reduction: 33% Agrp, 21% Bgrp |
| Notes |
Survival rates for Duke's stage: A = 94.3%, B = 84.4%, C = 56.6%, D = 2.5% |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
